Recommendations for selecting drug-drug interactions for clinical decision support

American Journal of Health-System Pharmacy

Volumn 73, Issue 8, 2016, Pages 576-585

  Tilson, Hugh ^a   Hines, Lisa E ^b   McEvoy, Gerald ^c   Weinstein, David M ^d   Hansten, Philip D ^e   Matuszewski, Karl ^f   Le Comte, Marianne ^c   Higby Baker, Stefanie ^g   Hanlon, Joseph T ^h   Pezzullo, Lynn ^b   Vieson, Kathleen ⁱ   Helwig, Amy L ^j   Huang, Shiew Mei ^k   Perre, Anthony ^l   Bates, David W ^m   Poikonen, John ⁿ   Wittie, Michael A ^j   Grizzle, Amy J ^o   Brown, Mary ^o   Malone, Daniel C ^o  

^a University of North Carolina at Chapel Hill   (United States)

^b Pharmacy Quality Alliance   (United States)

^c AMERICAN SOCIETY OF HEALTH SYSTEM PHARMACISTS   (United States)

^d Wolters Kluwer Health   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f First Databank   (United States)

^g Cerner Multum   (United States)

^h UNIVERSITY OF PITTSBURGH   (United States)

ⁱ ELSEVIER MASSON   (France)

^j U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

^k CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^l CANCER TREATMENT CENTERS OF AMERICA   (United States)

^m HARVARD MEDICAL SCHOOL   (United States)

ⁿ UNIVERSITY OF MASSACHUSETTS LOWELL   (United States)

^o UNIVERSITY OF ARIZONA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IBRUTINIB; NITRIC ACID DERIVATIVE; SILDENAFIL;

ARTICLE; CLINICAL DECISION MAKING; CLINICAL PRACTICE; DECISION SUPPORT SYSTEM; DRUG DRUG INTERACTION; DRUG INTERACTION; DRUG PACKAGING; ELECTRONIC MEDICAL RECORD; FEEDBACK SYSTEM; HEALTH CARE POLICY; HUMAN; MEDICAL INFORMATION; PATIENT SAFETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; RISK MANAGEMENT; ALERT FATIGUE (HEALTH CARE); CLINICAL DECISION SUPPORT SYSTEM; CONSENSUS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; PHYSICIAN ORDER ENTRY SYSTEM; PREVENTION AND CONTROL; STANDARDS; UNITED STATES;

ALERT FATIGUE, HEALTH PERSONNEL; CLINICAL DECISION-MAKING; CONSENSUS; DECISION SUPPORT SYSTEMS, CLINICAL; DRUG INTERACTIONS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; MEDICAL ORDER ENTRY SYSTEMS; UNITED STATES;

EID: 84964026763     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp150565     Document Type: Article

References (66)

1. Aspden P, Wolcott JA, Bootman JL, Cronenwett, eds. Preventing medication errors: Quality chasm series. www.iom.edu/Reports/2006/Preventing-Medication-Errors-Quality-Chasm-Series.aspx (accessed 2014 Apr 22).
2. Chaffee BW, Zimmerman CR. Developing and implementing clinical decision support for use in a computerized prescriber-order-entry system. Am J Health-Syst Pharm. 2010; 67:391-400.
3. Hansten PD, Horn JR, Hazlet TK. ORCA: OpeRational ClassificAtion of drug interactions. J Am Pharm Assoc. 2001; 41:161-5.
4. Centers for Medicare and Medicaid Services. Eligible professional meaningful use core measures: Measure 2 of 13 www.cms.gov/Regulations-and-Guidance/Legislation/EHRIncentivePrograms/downloads/2-Drug-Interaction-ChecksEP.pdf (accessed 2013 Jan 9).
5. Blumenthal D, Tavenner M. The "meaningful use" regulation for electronic health records. N Engl J Med. 2010; 363:501-4.
6. Kesselheim AS, Cresswell K, Phansalkar S et al. Clinical decision support systems could be modified to reduce 'alert fatigue' while still minimizing the risk of litigation. Health Aff. 2011; 30:2310-7.
7. Jankel CA, Martin BC. Evaluation of six computerized drug interaction screening programs. Am J Hosp Pharm. 1992; 49:1430-5.
8. Cavuto NJ, Woosley RL, Sale M. Pharmacies and prevention of potentially fatal drug interactions. JAMA. 1996; 275:1086-7.
9. Hazlet TK, Lee TA, Hansten PD, Horn JR. Performance of community pharmacy drug interaction software. J Am Pharm Assoc. 2001; 41:200-4.
10. Smith WD, Hatton RC, Fann AL et al. Evaluation of drug interaction software to identify alerts for transplant medications. Ann Pharmacother. 2005; 39:45-50.
11. Abarca J, Colon LR, Wang VS et al. Evaluation of the performance of drug-drug interaction screening software in community and hospital pharmacies. J Manag Care Pharm. 2006; 12:383-9.
12. Saverno KR, Hines LE, Warholak TL et al. Ability of pharmacy clinical decision-support software to alert users about clinically important drug-drug interactions. J Am Med Inform Assoc. 2011; 18:32-7.
13. Metzger J, Welebob E, Bates DW et al. Mixed results in the safety performance of computerized physician order entry. Health Aff. 2010; 29:655-63.
14. Hatton RC, Rosenberg AF, Morris CT et al. Evaluation of contraindicated drug-drug interaction alerts in a hospital setting. Ann Pharmacother. 2011; 45:297-308.
15. Shah NR, Seger AC, Seger DL et al. Improving acceptance of computerized prescribing alerts in ambulatory care. J Am Med Inform Assoc. 2006; 13:5-11.
16. Murphy JE, Forrey RA, Desiraju U. Community pharmacists' responses to drug-drug interaction alerts. Am J Health-Syst Pharm. 2004; 61:1484-7.
17. Weingart SN, Simchowitz B, Shiman L et al. Clinicians' assessments of electronic medication safety alerts in ambulatory care. Arch Intern Med. 2009; 169:1627-32.
18. Van Der Sijs H, Aarts J, Vulto A, Berg M. Overriding of drug safety alerts in computerized physician order entry. J Am Med Inform Assoc. 2006; 13:138-47.
19. Isaac T, Weissman JS, Davis RB et al. Overrides of medication alerts in ambulatory care. Arch Intern Med. 2009; 169:305-11.
20. Bryant AD, Fletcher GS, Payne TH. Drug interaction alert override rates in the meaningful use era. No evidence of progress. Appl Clin Inform. 2014; 5:802-13.
21. Scheife RT, Hines LE, Boyce RD et al. Consensus recommendations for systematic evaluation of drug-drug interaction evidence for clinical decision support. Drug Saf. 2015; 38:197-206.
22. Payne TH, Hines LE, Chan RC et al. Recommendations to improve the usability of drug-drug interaction clinical decision support alerts. J Am Med Inform Assoc. 2015; 22:1243-50.
23. Phansalkar S, Desai AA, Bell D et al. High-priority drug-drug interactions for use in electronic health records. J Am Med Inform Assoc. 2012; 19:735-43.
24. Phansalkar S, Van Der Sijs H, Tucker AD et al. Drug-drug interactions that should be non-interruptive in order to reduce alert fatigue in electronic health records. J Am Med Inform Assoc. 2013; 20:489-93.
25. Sox HC. Assessing the trustworthiness of the guideline for management of high blood pressure in adults. JAMA. 2014; 311:472-4.
26. Graham R, Mancher M, Wolman DM et al., eds. Clinical practice guidelines we can trust. www.iom.edu/Reports/2011/Clinical-Practice-Guidelines-We-Can-Trust.aspx (accessed 2014 Apr 22).
27. Guyatt GH, Oxman AD, Vist GE et al. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008; 336:924-6.
28. Marriott J, Stehlik P. A critical analysis of the methods used to develop explicit clinical criteria for use in older people. Age Ageing. 2012; 41:441-50.
29. Ridgeley MS, Greenberg MD. Too many alerts, too much liability: Sorting through the malpractice implications of drug-drug interaction clinical decision support. St Louis U J Health Law Policy. 2012; 5:257-96.
30. Hoffman S, Podgurski A. Drug-drug interaction alerts: Emphasizing the evidence. St Louis U J Health Law Policy. 2012; 5:297-309.
31. Weingart SN, Seger AC, Feola N et al. Electronic drug interaction alerts in ambulatory care: The value and acceptance of high-value alerts in US medical practices as assessed by an expert clinical panel. Drug Saf. 2011; 34:587-93.
32. University of Liverpool. HIV-drug interactions. www.hiv-druginteractions.org (accessed 2014 Dec 1).
33. University of Liverpool. HEP-drug interactions. www.hep-druginteractions.org (accessed 2014 Dec 1).
34. Floor-Schreudering A, Geerts AF, Aronson JK et al. Checklist for standardized reporting of drug-drug interaction management guidelines. Eur J Clin Pharmacol. 2014; 70:313-8.
35. Khoo S, Gibbons S, Seden K, Black D. Systematic review: Drug-drug interactions between antiretrovirals and medications used to treat TB, malaria, hepatitis B and C and opioid dependence. www.who.int/hiv/topics/treatment/drug-drug-interactions-review.pdf (accessed 2014 Apr 22).
36. Guyatt GH, Oxman AD, Vist GE et al. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008; 336:924-6.
37. GRADE Working Group. Organizations that have endorsed or that are using GRADE. www.gradeworkinggroup.org/society/index.htm (accessed 2014 Jul 28).
38. Hines LE, Malone DC, Murphy JE. Recommendations for generating, evaluating, and implementing drug-drug interaction evidence. Pharmacotherapy. 2012; 32:304-13.
39. Schunemann HJ, Best D, Vist G, Oxman AD. Letters, numbers, symbols and words: How to communicate grades of evidence and recommendations. CMAJ. 2003; 169:677-80.
40. Wright A, Sittig DF, Ash JS et al. Governance for clinical decision support: Case studies and recommended practices from leading institutions. J Am Med Inform Assoc. 2011; 18:187-94.
41. Van Roon EN, Flikweert S, le Comte M et al. Clinical relevance of drug-drug interactions: A structured assessment procedure. Drug Saf. 2005; 28:1131-9.
42. Horsky J, Schiff GD, Johnston D et al. Interface design principles for usable decision support: A targeted review of best practices for clinical prescribing interventions. J Biomed Inform. 2012; 45:1202-16.
43. Talbot JC, Aronson JK, Stephens MD. Stephens' detection and evaluation of adverse drug reactions: Principles and practice. 6th ed. West Sussex, United Kingdom: Wiley; 2011.
44. Ashworth M. Re: GPs' views on computerized drug interaction alerts. J Clin Pharm Ther. 2002; 27:311-2.
45. Calman KC. Cancer: Science and society and the communication of risk. BMJ. 1996; 313:799-802.
46. European Commission Enterprise and Industry Directorate-General. A guideline on summary of product characteristics (September 2009). http://ec.europa.eu/health/files/eudralex/vol-2/c/smpc-guideline-rev2-en.pdf (accessed 2015 Mar 2).
47. Tamblyn R, Eguale T, Buckeridge DL et al. The effectiveness of a new generation of computerized drug alerts in reducing the risk of injury from drug side effects: A cluster randomized trial. J Am Med Inform Assoc. 2012; 19:635-43.
48. Kawamoto K, Houlihan CA, Balas EA, Lobach DF. Improving clinical practice using clinical decision support systems: A systematic review of trials to identify features critical to success. BMJ. 2005; 330:765.
49. Bates DW, Kuperman GJ, Wang S et al. Ten commandments for effective clinical decision support: Making the practice of evidence-based medicine a reality. J Am Med Inform Assoc. 2003; 10:523-30.
50. Viagra (sildenafil citrate) package insert. New York: Pfizer Laboratories; 2014.
51. Werns SW. Are nitrates safe in patients who use sildenafil? Maybe. Crit Care Med. 2007; 35:1988-90.
52. Anderson JL, Adams CD, Antman EM et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): Developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation. 2007; 116:e148-304.
53. U.S. National Library of Medicine. DailyMed. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0dfd0279-ff17-4ea9-89be-9803c71bab44 (accessed 2015 May 5).
54. Miller AM, Boro MS, Korman NE, Davoren JB. Provider and pharmacist responses to warfarin drug-drug interaction alerts: A study of healthcare downstream of CPOE alerts. J Am Med Inform Assoc. 2011; 18(suppl 1):i45-50.
55. Van Der Sijs H, Aarts J, Van Gelder T et al. Turning off frequently overridden drug alerts: Limited opportunities for doing it safely. J Am Med Inform Assoc. 2008; 15:439-48.
56. Gardner RM, Evans RS. Using computer technology to detect, measure, and prevent adverse drug events. J Am Med Inform Assoc. 2004; 11:535-6.
57. Riedmann D, Jung M, Hackl WO et al. Development of a context model to prioritize drug safety alerts in CPOE systems. BMC Med Inform Decis Mak. 2011; 11:35.
58. Teich JM, Osheroff JA, Pifer EA et al. Clinical decision support in electronic prescribing: Recommendations and an action plan: Report of the joint clinical decision support workgroup. J Am Med Inform Assoc. 2005; 12:365-76.
59. Kuperman GJ, Bobb A, Payne TH et al. Medication-related clinical decision support in computerized provider order entry systems: A review. J Am Med Inform Assoc. 2007; 14:29-40.
60. Weingart SN, Toth M, Sands DZ et al. Physicians' decisions to override computerized drug alerts in primary care. Arch Intern Med. 2003; 163:2625-31.
61. Tamblyn R, Huang A, Taylor L et al. A randomized trial of the effectiveness of on-demand versus computer-triggered drug decision support in primary care. J Am Med Inform Assoc. 2008; 15:430-8.
62. Seidling HM, Klein U, Schaier M et al. What, if all alerts were specific-estimating the potential impact on drug interaction alert burden. Int J Med Inform. 2014; 83:285-91.
63. Ammenwerth E, Hackl WO, Riedmann D, Jung M. Contextualization of automatic alerts during electronic prescription: Researchers' and users' opinions on useful context factors. Stud Health Technol Inform. 2011; 169:920-4.
64. Duke JD, Bolchini D. A successful model and visual design for creating context-aware drug-drug interaction alerts. AMIA Annu Symp Proc. 2011; 2011:339-48.
65. Van Den Bemt PM, Egberts AC, Lenderink AW et al. Risk factors for the development of adverse drug events in hospitalized patients. Pharm World Sci. 2000; 22:62-6.
66. Ko Y, Malone DC, D'Agostino JV et al. Potential determinants of prescribers' drug-drug interaction knowledge. Res Social Adm Pharm. 2008; 4:355-66.